OUR PRODUCTS
FORMULATION

Each film-coated tablet contains: Cefixime (as trihydrate) eq. to Cefixime, 200mg.

DOSAGE AND ADMINISTRATION

The usual adult dose of Cefixime (anhydrous) is 200-400 mg per day administered orally either as a single dose or in two divided doses, although lower doses may prove sufficient to treat uncomplicated urinary tract infections. For children, 8mg/kg daily, as either a single dose or two divided doses is recommended. Or as prescribed by a physician.

INDICATION

Alternative treatment of urinary tract infections, otitis media, respiratory infections caused by susceptible organisms including penicillin suspectible S. pneumonia, S. pyrogenes, H. influenza and Enterobacteriaceae with documented poor compliance or poor response to conventional oral antibiotics, outpatient therapy of serious soft tissue or skeletal infection due to susceptible organisms and single dose treatment of uncomplicated cervical/urethral gonorrhea.

CONTRAINDICATION

Patient with known hypersensitivity to cephalosporin antibiotic.

PRECAUTIONS

Cefixime is generally well tolerated. The majority of adverse reactions observed in clinical trials were mild and self limiting in nature. Gastrointestinal Disturbance: The most frequent side effects with Cefixime are diarrhea and stool changes. Some cases of moderate to severe diarrhea have been reported; this has occasionally warranted cessation of therapy. Cefixime should be discontinued if marked diarrhea occurs. Other gastrointestinal side effects seen less frequently are nausea, abdominal pain, dyspepsia, vomiting and flatulence. Pseudomembranous colitis has been reported. Central Nervous System: Headache and dizziness. Hypersensitivity Reactions: Allergies in the form of rash, pruritus, urticaria, drug fever and arthralgia have been observed. These reactions usually subsided upon discontinuation of therapy. Haemotologic and Clinical Chemistry: Thrombocytopenia and leucopenia and eosinophilia have been reported. These reactions were infrequent and reversible. Mild transient changes in liver and renal function tests have been observed.

GERMANY
KOHLENSERSLAUTERN
67663 KAISERSLAUTERN
GERMANY

ASIA PACIFIC - PHILIPPINES
2204-C West Tektite Tower, Philippine Stock Exchange Center Exchange Rd.,
Ortigas Center, Pasig City,
Philippines

EMAIL
eisaac@verheilenpharma.com
info@verheilen.com
info@verheilenpharma.com

Verheilen Pharmaceuticals Inc. © 2015 All rights reserved.

Translate »